ArticleThe Journal of antimicrobial chemotherapy2026
Evolving landscape of methicillin-resistant Staphylococcus pseudintermedius: the emergence of new epidemic waves across Europe, Asia and North America.
Article in The Journal of antimicrobial chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Article
- Isolation of a Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Distinct genetic programs drive antibiotic resistance and intracellular invasion in emerging MRSA strains.mSystems · 2026Article
- Diversity among isolates of Staphylococcus intermedius group from Pacific marine mammals of Southern California.PloS one · 2026Article
- Tetracycline Resistance Among Canine Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveThis study aims to identify spatiotemporal variations in clonal diversity and antimicrobial resistance of methicillin-resistant Staphylococcus pseudintermedius (MRSP). MATERIALS AND
methodsA PubMed search (June 2016-December 2023), combined with data from PubMLST and a previous review (September 2007-May 2016), identified 2654 isolates. Multinomial logistic regression (MLR) and Bayesian regression models (BRMs) were used to assess associations between clonal complexes (CCs) and variables (sample type, continent and period), with MLR results feeding into the BRM.
resultsA shift in MRSP clonal structure was observed after 2013. A decline in the prevalence of historically dominant lineages, such as CC71 in Europe, CC68 in North America and CC45 in Asia, coincided with the global emergence of CC551, as well as CC556 and CC1431 in North America, and CC363 and CC1631 in Asia. Resistance to non-β-lactams increased in North America, particularly for chloramphenicol (6%-59%), remained largely stable in Europe except for tetracycline, and decreased in Asia. Striking differences among CCs were observed, with CC71 exhibiting the highest resistance rates and a greater likelihood of being isolated from clinical samples. DISCUSSION: The observed associations between specific CCs and resistance patterns provide valuable insights into the factors driving these epidemiological changes, including regional antimicrobial use patterns (e.g. chloramphenicol usage in North America) and potential fitness advantages of emerging lineages. These dynamics parallel those seen in methicillin-resistant Staphylococcus aureus.
conclusionThe evolving MRSP landscape highlights the need for sustained global surveillance to monitor clonal diversity, antimicrobial use and resistance trends.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.